SEC 13F Intelligence

Managers / Q1 2022 · view latest →

Athyrium Capital Management, LP

CIK 0001728001 · 505 FIFTH AVENUE, FLOOR 18, NEW YORK, NY, 10017 · 212-402-6925

Reported Value
$281M
Q1 2022
Positions
10
Filings on Record
21
2019–present window
Filed
May 16, 2022
original filing

Summary

Athyrium Capital Management, LP reported $281M in U.S.-listed holdings across 10 positions for Q1 2022.

The portfolio is heavily concentrated: Progenity alone accounts for 38.5% of reported value.

Compared with Q4 2021, the fund opened 4 new positions and exited 0.

Portfolio Metrics

Turnover
+18.8%
vs prior filed quarter
Largest Position
+38.5%
Progenity

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $104MQ4 ’18Q1 ’19: $98MQ2 ’19: $9MQ3 ’19: $5MQ3 ’19Q4 ’20: $208MQ1 ’21: $198MQ2 ’21: $240MQ2 ’21Q3 ’21: $158MQ4 ’21: $280MQ1 ’22: $281MQ1 ’22Q2 ’22: $238MQ3 ’22: $267MQ4 ’22: $238MQ4 ’22Q1 ’23: $279MQ2 ’23: $154MQ3 ’23: $114MQ3 ’23Q4 ’23: $69MQ1 ’24: $73MQ2 ’24: $34MQ2 ’24Q3 ’24: $9Mfilingsflow.com

Portfolio Composition

By security type
Other: 55.2%US DOMESTIC: 41.6%Common Stock: 3.2%
  • Other · 55.2% · $155M
  • US DOMESTIC · 41.6% · $117M
  • Common Stock · 3.2% · $9M

Quarter-over-Quarter Changes full breakdown →

vs Q4 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
Omeros CorpNEW+21.00M21.00M+$20M$20M
Omeros CorpNEW+18.00M18.00M+$14M$14M
BridgeBio Pharma Inc.NEW+20.00M20.00M+$10M$10M
PBYIPUMA BIOTECHNOLOGY INCNEW+1.79M1.79M+$5M$5M
Progenity Inc.HELD+029.86M−$28M$35M
Amryt Pharma PLCHELD+08.86M−$22M$73M
RVL PHARMACEUTICALS PLCHELD+08.15M+$5M$14M
Progenity Inc.HELD+0103.50M−$2M$74M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2022

8 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1Progenity Inc.Note 7.250% 12/0 · COM38.51%$108M133.36M
2Amryt Pharma PLCSponsored ADS26.04%$73M8.86M
3Omeros CorpNOTE 6.250%11/1 · NOTE 5.250% 2/111.95%$34M39.01M
4CAREMAX INCCOM CL A11.92%$34M4.49M
5RVL PHARMACEUTICALS PLCSHS4.90%$14M8.15M
6BridgeBio Pharma Inc.NOTE 2.250% 2/03.44%$10M20.00M
7PBYIPUMA BIOTECHNOLOGY INChistory →COM1.83%$5M1.79M
8RAHSocietal CDMO Inc.history →Com1.41%$4M2.20M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2024$9M2Nov 12, 202413F-HRchanges · EDGAR ↗
Q2 2024$34M3Aug 8, 202413F-HRchanges · EDGAR ↗
Q1 2024$73M3May 16, 202413F-HRchanges · EDGAR ↗
Q4 2023$69M3Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$114M6Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$154M7Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$279M8May 16, 2023RESTATEMENTchanges · EDGAR ↗
Q4 2022$238M11Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$267M11Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$238M11Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$281M10May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$280M6Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$158M5Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$240M5Aug 16, 202113F-HRchanges · EDGAR ↗
Q1 2021$198M4May 17, 202113F-HRchanges · EDGAR ↗
Q4 2020$208M3Feb 16, 202113F-HRchanges · EDGAR ↗
Q3 2019$5M1Nov 14, 201913F-HRchanges · EDGAR ↗
Q2 2019$9M1Aug 14, 201913F-HRchanges · EDGAR ↗
Q1 2019$98M2May 15, 201913F-HRchanges · EDGAR ↗
Q4 2018$104M3Feb 12, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.